 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LNK01002 / Lynk Pharmaceuticals
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 18, 2023
P1, N=0, Withdrawn, Sponsor: Lynk Pharmaceuticals Co., Ltd
N=93 --> 0 | Trial completion date: Dec 2023 --> Oct 2022 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2023 --> Oct 2022
- | LNK01002 / Lynk Pharmaceuticals
New P1 trial: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (clinicaltrials.gov) - May 20, 2021
P1, N=93, Recruiting, Sponsor: Lynk Pharmaceuticals Co., Ltd